Halozyme Therapeutics In $83M Licensing Deal

San Diego-based Halozyme Therapeutics, a developer of products for the insulin, cancer, dermatology and drug delivery markets, said today along with ViroPharma Incorporate that it is in a $83M licensing deal. The two said that Halozyme has received a $9M upfront payment and potential future milestone payments of $74M depending on meeting clinical and regulatory targets. The deal also includes a 10% royalty. The joint effort is focused on treating hereditary angioedema (HAE).